Overactive Bladder and the β3-Adrenoceptor Agonists: Current Strategy and Future Prospects

Drugs
Ilias GiarenisLinda Cardozo

Abstract

Overactive bladder (OAB) is a clinical syndrome describing the symptom complex of urgency, with or without urgency incontinence, and is usually associated with frequency and nocturia. It is a common, under-diagnosed and therefore under-treated condition that can have a detrimental effect on physical functioning and psychological well-being. Initial treatment of OAB includes lifestyle advice, behavioural modifications, bladder retraining and pelvic floor muscle training, usually in combination with antimuscarinic agents. The β3-adrenoceptor agonist mirabegron is the first of a new class of drugs that are now competing with the more established antimuscarinics for the treatment of OAB. Our review focuses on the mode of action, efficacy and tolerability of mirabegron. The place of β3-adrenoceptor agonists in the treatment algorithm of OAB is discussed, considering the adverse events associated with antimuscarinics. Drug therapy tailored to different population groups appears a promising future prospect. Development of other β3-adrenoceptor agonists is expected, and combination therapy regimens might revolutionise the treatment of OAB.

References

Jan 9, 1998·British Journal of Obstetrics and Gynaecology·C J KelleherS Salvatore
May 15, 2002·Urology·Osamu Yamaguchi
Dec 25, 2003·Lancet Neurology·Karl-Erik Andersson
Jul 23, 2004·Physiological Reviews·Karl-Erik Andersson, Anders Arner
Mar 4, 2009·International Braz J Urol : Official Journal of the Brazilian Society of Urology·Pradeep TyagiMichael B Chancellor
Mar 13, 2009·BJU International·Debra E IrwinCon Kelleher
Nov 17, 2009·BJU International·Joshua S BennerLinda Brubaker
Dec 21, 2010·European Urology·Karl-Erik Andersson
May 4, 2012·Naunyn-Schmiedeberg's Archives of Pharmacology·Itaru MaruyamaHiroshi Kusama
Oct 20, 2012·The Journal of Urology·Victor W NittiSender Herschorn
Feb 12, 2013·Maturitas·Dudley RobinsonLinda Cardozo
May 16, 2013·BMJ : British Medical Journal·Edward J MillsJohn P A Ioannidis
Oct 5, 2013·Clinical Therapeutics·Michael B ChancellorDenise Globe
Oct 22, 2013·The Journal of Urology·Paul W Veenboer, J L H Ruud Bosch
May 23, 2014·Neurourology and Urodynamics·Ann T Hanna-MitchellCara Tannenbaum
Nov 8, 2014·International Urogynecology Journal·Emilio Sacco, Riccardo Bientinesi
Jan 27, 2015·JAMA Internal Medicine·Shelly L GrayEric B Larson
Jan 28, 2015·The Journal of Urology·E Ann GormleyUNKNOWN Society of Urodynamics, Female Pelvic Medicine
Mar 11, 2015·European Journal of Obstetrics, Gynecology, and Reproductive Biology·Aswini A Balachandran, Jonathan R A Duckett
Nov 1, 2014·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·A WaggT Berner

❮ Previous
Next ❯

Citations

Feb 8, 2018·Molecular & Cellular Proteomics : MCP·Edmond Changkyun ParkGun-Hwa Kim

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.

Related Papers

Minerva ginecologica
Ilias Giarenis, Linda Cardozo
Expert Opinion on Drug Metabolism & Toxicology
Umberto Leone Roberti MaggioreSimone Ferrero
Expert Opinion on Investigational Drugs
Martino Maria ZaccheLinda Cardozo
© 2021 Meta ULC. All rights reserved